We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01621256
Recruitment Status : Recruiting
First Posted : June 18, 2012
Last Update Posted : December 8, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to determine whether ancrod is effective and safe in the treatment of sudden sensorineural hearing loss (SSHL).

Condition or disease Intervention/treatment Phase
Hearing Loss Deafness Hearing Loss, Sensorineural Hearing Disorders Ear Diseases Drug: Ancrod Drug: Saline solution Phase 1 Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 115 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-blind, Randomized, Placebo-controlled Study on Efficacy, Safety and Tolerability of Ancrod in Patients With Sudden Sensorineural Hearing Loss (SSHL)
Study Start Date : May 2013
Estimated Primary Completion Date : August 2018
Estimated Study Completion Date : October 2018

Arms and Interventions

Arm Intervention/treatment
Experimental: Ancrod
Drug: Ancrod
Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
Other Names:
  • Viprinex
  • NM-V
Placebo Comparator: Saline solution
Saline solution
Drug: Saline solution
Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
Other Name: Placebo

Outcome Measures

Primary Outcome Measures :
  1. Change in PTA (pure tone audiogram) in the affected ear [ Time Frame: From baseline to Day 8 ]

Secondary Outcome Measures :
  1. Change in speech recognition in the affected ear [ Time Frame: From baseline to Day 8 ]

Other Outcome Measures:
  1. Patient assessment of change in hearing impairment [ Time Frame: From baseline to Day 8, Day 30 and Day 90 ]
  2. Change in fibrinogen concentration [ Time Frame: From baseline to Day 2 and Day 8 ]
  3. Change in biomarkers [ Time Frame: From baseline to Day 8 ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Unilateral idiopathic sudden sensorineural hearing loss ≥30 dB
  • Symmetric hearing prior to onset of SSHL
  • Enrollment has to be accomplished within 7 days after SSHL onset

Exclusion Criteria:

  • Bilateral SSHL
  • Incomplete recovery after previous SSHL
  • Previously existing, known retrocochlear hearing loss
  • Any history of any ear operation or local inflammatory disease in the past one year
  • History of blunt or penetrating ear trauma, head trauma, barotrauma, or acoustic trauma immediately preceding SSHL
  • History of Meniere's disease, autoimmune hearing loss, radiation-induced hearing loss, endolymphatic hydrops.
  • Treatment with steroids for any reason within the preceding 30 days.
  • Body weight > 140 kg
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01621256

Contact: Maike Melullis +49-4122-712-0 maike.melullis@nordmark-pharma.de

Site CZ Recruiting
Hradec Králové, Czechia
Site CZ Recruiting
Praha, Czechia
Site D Recruiting
Bad Schönborn, Germany
Site D Recruiting
Göttingen, Germany
Site D Recruiting
Hamburg, Germany
Site D Recruiting
Hannover, Germany
Site D Recruiting
Landsberg am Lech, Germany
Site D Recruiting
München, Germany
Sponsors and Collaborators
Nordmark Arzneimittel GmbH & Co. KG
ClinSupport GmbH
MWI Medizinisches Wirtschaftsinstitut GmbH
ProjectPharm s.r.o.
LCR Leading Clinical Research s.r.o.
X-act Cologne Clinical Research GmbH
Principal Investigator: Martin Canis, MD PhD Department for Otorhinolaryngology, LM University Munich
More Information

Responsible Party: Nordmark Arzneimittel GmbH & Co. KG
ClinicalTrials.gov Identifier: NCT01621256     History of Changes
Other Study ID Numbers: NM-V-101
2012-000066-37 ( EudraCT Number )
First Posted: June 18, 2012    Key Record Dates
Last Update Posted: December 8, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Hearing Disorders
Hearing Loss
Ear Diseases
Hearing Loss, Sensorineural
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Pharmaceutical Solutions
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action